ArticleJournal of neuro-oncology2025
Global burden of brain and central nervous system cancer in 185 countries, and projections up to 2050: a population-based systematic analysis of GLOBOCAN 2022.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Healthcare utilization and 30-day in-hospital costs following brain tumor surgery: A single-center, retrospective cohort study.Neuro-oncology practice · 2026Article
- Multifaceted biological activities of linalool: antimicrobial, antibiofilm, cytotoxic, antiproliferative and caspase-3/7 activity.World journal of microbiology & biotechnology · 2026Article
- Epidemiological analysis of brain tumours in dogs in Australia between 1994 and 2024.Scientific reports · 2026Article
- Platelet-to-Albumin Ratio and Clinical Outcomes in IDH-Wildtype Grade 4 Diffuse Glioma.Journal of clinical medicine · 2026Article
- Article
- Review
- CAR T-cells for the treatment of CNS malignancies.Frontiers in immunology · 2026Review
- Neurooncology: 2026 update.Free neuropathology · 2026Review
- Acute anti-proliferative and anti-migratory effects of cannabidiol on C6 rat glioma, SH-SY5Y human neuroblastoma, and HT22 mouse hippocampal neuronal cell cultures.Frontiers in toxicology · 2026Article
- Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma.Frontiers in pharmacology · 2026Article
- The HALLMOUNT Score: Development of a Novel Multidimensional Prognostic Model for Solid Tumors, with Initial Clinical Application in Grade 4 Adult-Type Diffuse Gliomas.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBrain and central nervous system (CNS) cancers are associated with high mortality and morbidity. Here, we aimed to systematically evaluate and compare brain and CNS cancer between pediatric and adult populations.
methodsThis study utilized the GLOBOCAN 2022 database to analyze incidence and mortality estimates for brain and CNS cancers across 185 countries and territories in 2022. Joinpoint regression was employed to estimate the average annual percent change in age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR).
resultsIn 2022, the global estimated ASIR of brain and CNS cancers was 3.5 per 100,000 people, with 321,624 new cases. An estimated 248,403 deaths were attributed to brain and CNS cancer, with an ASMR of 2.6 per 100,000 people. In 2022, pediatric brain and CNS cancers in individuals aged 0-14 years ranked second globally for both incidence and mortality across various cancer subtypes, while for individuals aged ≥ 15 years, they ranked 19th and 12th, respectively. Globally, the mortality-to-incidence ratios of brain and CNS cancer were 47.7% in pediatrics aged 0-14 years and 77.8% in individuals aged ≥ 15 years, respectively. By 2050, if current trends persist, brain and CNS cancer among individuals aged 0-14 years is projected to decrease by 9.2% globally, but this trend is limited to countries with higher Human Development Index (HDI). Among individuals aged ≥ 15 years, if incidence rates remain constant, global estimated cases of brain and CNS cancer are projected to increase by 32.9% by 2050 and all HDI subgroups are predicted to experience an upward trend in incidence, with the magnitude of increase being more significant in lower HDI up to 2050.
conclusionThis study identified substantial geographical and socioeconomic inequalities in the brain and CNS cancers globally, with potential underreporting concerns in pediatric cases and increasing burdens predicted up to 2050, particularly in lower HDI countries.
Indexed as
Identifiers
40720078What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.